Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Feb. 15, 2012 - PRLog -- GlobalData estimates that the global aplastic anemia therapeutics market was worth $73.3m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.1% to reach $79.7m by 2019. The current treatment options for aplastic anemia include allogeneic stem cell transplant and immunosuppressive therapy which are primarily dominated by generics. There is no promising, industrysponsored molecule in the late stage pipeline. Owing to these factors, the aplastic anemia market is expected to show slow growth until 2019.

Current treatment options for aplastic anemia are allogeneic stem cell transplant or immunosuppressive therapy. Although these therapies are effective in approximately 70% of patients, stem cell transplant is associated with the risk of developing graft failure and graft-versus-host disease (GVHD). Chances of relapse and further development to myelodysplastic syndrome (MDS) limit the use of immunosuppressive therapy. Therefore, a moderate unmet need exists in the treatment of aplastic anemia.

The aplastic anemia market is moderately served by the currently marketed products as these are effective only in approximately 70% of patients, and are associated with serious complications and relapses. Therefore, the aplastic anemia market offers adequate opportunity for new entrants who can develop drugs that can reduce the chances of graft rejection, GVHD and relapses, together with better efficacy and safety profiles.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages....


GlobalData’s analysis of the entire pipeline landscape shows that the late stage pipeline does not offer any immediate hope for aplastic anemia patients. There is no molecule in Phase III of development. The only molecule in Phase II/III is alemtuzumab. Alemtuzumab is under investigation as a conditioning regimen for patients with severe aplastic anemia who are undergoing allogeneic stem cell transplantation using matched unrelated donors and mismatched related donors, which is a very small set of patients. The trial is sponsored by the Mayo Clinic. Eltrombopag, which is currently under Phase II development, may give some hope for aplastic anemia patients and could be launched by 2018, driving the growth of the aplastic anemia market. This trial was initiated by the National Heart, Lung, and Blood Institute (NHLBI) in March 2011.

GlobalData, the industry analysis specialist, has released its new report, “Aplastic Anemia Therapeutics
- Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global aplastic anemia therapeutics market. The report identifies the key trends shaping and driving the global aplastic anemia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global aplastic anemia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Apla...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.